An Open Label, Single Arm, Multicentre Study to Assess the Clinical Effectiveness and Safety of Lynparza (Olaparib) Capsules Maintenance Monotherapy in Platinum Sensitive Relapsed Somatic or Germline BRCA Mutated Ovarian Cancer Patients Who Are in Complete or Partial Response Following Platinum Based Chemotherapy (ORZORA)
Phase of Trial: Phase IV
Latest Information Update: 08 Jan 2018
At a glance
- Drugs Olaparib (Primary)
- Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Therapeutic Use
- Acronyms ORZORA
- Sponsors AstraZeneca
- 04 Jan 2018 Planned End Date changed from 3 Jun 2019 to 22 Nov 2019.
- 04 Jan 2018 Planned primary completion date changed from 3 Jun 2019 to 22 Nov 2019.
- 04 Oct 2017 Planned End Date changed from 2 Jan 2019 to 3 Jun 2019.